DIAMYD INFORMATION

Press Release, Stockholm, Sweden, December 13, 2007 – Diamyd Medical AB (www.omxgroup.com, ticker: DIAM B; www.otcqx.com, ticker DMYDY)

Diamyd Medical announced today that the leaving Director of Research and Development John Robertson has sold shares in the Company.

”Robertson has been on sick leave since the month of June and will be leaving the Company as the responsibility for manufacturing has been transferred to our US office in Pittsburgh. That he chooses to dispose of his shares must solely be due to personal reasons, as far as I can understand. Robertson has not been in contact with the Company during the sick leave and has thus not had any insight into Diamyd Medical since June,” says Anders Essen-Moller, chairman of the Company. “We are looking forward to the 30 month results from the type 1 diabetes study beginning of 2008 and to file our Phase III application in the US before the end of this year.”